Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies

Read full text
Authors: Alberico L. Catapano, Elina Mikhailova, Ann Marie Navar, Puja Banka, Pablo Corral, Manish Saxena, P.Gabriel Steg, Subodh Verma, Andrew Yacoub Kordahi, Geraldine Mendizabal, Pengfei Zhu, Christie M. Ballantyne
+39 more Chau-Chung Wu, Chii‐Min Hwu, Kai‐Chien Yang, Ping-Yen Liu, Kuo-Chun Hung, Sybil Charriere, Bertrand Cariou, Gabriel Steg, Francois Roubille, Oren Caspi, Gil Moravsky, Victor Vishlitzky, Amos Katz, Carlos Brotons Cuixart, Francisco Jose Tinahones Madueno, Nuria Rial Lorenzo, María Urquizu-Padilla, Alex Vila Belmonte, Alfonso González, Devaki Nair, Manish Saxena, Umasuthan Srirangalingam, Cesar Javier Zaidman, Ezequiel Hector Vottero, Pablo Corral, Harold E. Bays, Frances Eileen Broyles, SHERYL M. MARKS, Shishir Kumar Khetan, Paul Gerard Matherne, Amit G. Shah, Ronald Stumbris, Jeffrey D. Wayne, Jean-francois Naud, A. Shekhar Pandey, Jean-Claude Tardif, Subodh Verma, John Vyselaar, Christie M. Ballantyne
Cited by: 11
References: 33

Abstract

BACKGROUND: Many adults fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals on statin monotherapy, requiring additional nonstatin lipid-lowering medication. Enlicitide, an oral proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor, lowered LDL-C by 60% compared with placebo; its efficacy compared with other oral nonstatin therapies has yet to be examined. OBJECTIVES: This study assessed the efficacy of enlicitide, a novel oral PCSK9 inhibitor, vs other oral nonstatin therapies. METHODS: In this phase 3, randomized, double-blind, active-comparator trial, statin-treated adults aged ≥18 years with LDL-C ≥55 mg/dL and a previous major atherosclerotic cardiovascular disease (ASCVD) event, or LDL-C ≥70 mg/dL if at intermediate to high risk for a first event, were randomized in 2:1:1:2 fashion to 20 mg enlicitide (n = 101), 180 mg bempedoic acid (n = 50), 10 mg ezetimibe (n = 50), or 180 mg bempedoic acid plus 10 mg ezetimibe (n = 100) once daily for 56 days. The primary endpoint was mean percentage change in LDL-C from baseline to day 56; secondary endpoints included mean percentage changes in apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (nonHDL-C). Safety endpoints included overall adverse events (AEs) and discontinuations due to AEs. RESULTS: Among 301 randomized participants (mean age 64.4 years, 37% female, 98% receiving moderate- to high-intensity statin), 298 (99.0%) completed the trial. The mean percentage change in LDL-C from baseline to day 56 was -64.6% (95% CI: -68.3% to -60.9%) with enlicitide, -6.3% (95% CI: -13.5% to 0.8%) with bempedoic acid, -27.8% (95% CI: -32.3% to -23.4%) with ezetimibe, and -36.5% (95% CI: -40.8% to -32.2%) with bempedoic acid plus ezetimibe; enlicitide was superior to each comparator (all P < 0.001). Reductions in ApoB and nonHDL-C were also greater with enlicitide (all P < 0.001). Proportions of participants with AEs and discontinuations due to AEs were similar across treatment arms. CONCLUSIONS: In statin-treated adults with a history of a major ASCVD event or at increased risk for a first event, enlicitide achieved greater reductions in LDL-C, ApoB, and nonHDL-C than other oral nonstatin therapies, demonstrating its potential role as an important add-on option when LDL-C goals are not met with the use of statins alone. (A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate [MK-0616, Oral PCSK9 Inhibitor] Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia [MK-0616-018] [CORALreef AddOn; NCT06450366).

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Cardiac Imaging and Diagnostics Cancer Lipids and Metabolism

Publication details

Journal / source
Journal of the American College of Cardiology
Publisher
Elsevier BV
Volume
88
Issue
3
Pages
340–352
Publication date
30 March 2026
Language
EN